Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cilazapril
- Development stage
- Phase 4
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cilazapril is an orally active angiotensin-converting enzyme (ACE) inhibitor used primarily to treat hypertension and heart failure. It acts as a prodrug that is hydrolyzed after absorption to its active form, cilazaprilat. Cilazapril works by competitively inhibiting ACE, thereby blocking the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This leads to decreased vasoconstriction and reduced aldosterone-mediated sodium and water reabsorption, resulting in lower blood pressure and reduced vascular resistance. Cilazapril may also be used for diabetic nephropathy to protect kidney function[1][4][5][6]. The drug has a pharmacological profile similar to other ACE inhibitors such as enalapril and ramipril[6].
- Brand names
- InhibaceAPO-CilazaprilMYLAN-Cilazapril
02
Targets
ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on cilazapril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cilazapril.